Rubicon award for innovative cancer drug delivery research
For his work on microrobot-based hydrogels Jianhong Wang has been awarded the prestigious Rubicon grant in the third round of 2024 to pursue groundbreaking research at the University of Oxford.
Rubicon award for innovative cancer drug delivery research
For his work on microrobot-based hydrogels Jianhong Wang has been awarded the prestigious Rubicon grant in the third round of 2024 to pursue groundbreaking research at the University of Oxford. This competitive program, funded by the Dutch Research Council (NWO), supports early-career scientists who show exceptional potential to become leaders in their fields. Wang will conduct a two-year project under the mentorship of Professor Molly Stevens, a renowned expert in bionanoscience and regenerative medicine.
Targeting tumor microenvironments
Wang鈥檚 project titled "Safe and Effective On-Demand Drug Delivery Using Microrobot-Based Hydrogels," aims to revolutionize cancer treatment by addressing limitations in current drug delivery methods. The research proposes a novel system that combines biocompatible microrobots with injectable hydrogels. These are designed to target tumor microenvironments with precision.
Microrobots for drug transport
The microrobots, developed by the Stevens Group, feature puffball-like structures with large inner cavities for efficient drug encapsulation and transport. By integrating nitric oxide (NO) donors on their surfaces, these microrobots achieve motility and enhanced tumor penetration. Additionally, embedding them in tumor-responsive hydrogels ensures prolonged retention and controlled release at target sites.
Improving cancer therapies
This innovative approach seeks to maximize tumor coverage, minimize side effects, and improve therapeutic outcomes, offering a promising alternative to conventional cancer treatments.
Nieuws
